Antipsychotic drug toxicology in children
- 15 March 2011
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 7 (5) , 591-608
Abstract
Introduction: There is an increasing use of antipsychotic drugs, particularly those of second- and third-generation, for a wide range of behavioral and affective disorders in pediatric and psychiatric practice. Limited data are available, however, regarding their safety and effectiveness, although children may be more vulnerable than adults to antipsychotic adverse effects because of developmental physiological changes that may affect their pharmacodynamic and pharmacokinetic profiles. Areas covered: This review covers the antipsychotics now specifically approved in major markets for children as well as those that are used in these patients for unapproved or off-label indications taking into account the potential differences in drug disposition and metabolism among children, adolescents and adults. MEDLINE and EMBASE international databases were searched for studies concerning the pharmacokinetics, efficacy and safety of first-, second- (‘atypical’) and third-generation antipsychotic agents. Expert opinion: Few studies have systematically monitored the safety of antipsychotics in young populations. Data concerning long-term side effects are especially limited, and a systematic benefit–risk evaluation is needed. When prescribing antipsychotics, physicians should, therefore, monitor patients closely for metabolic adverse events, hyperprolactinemia, extrapyramidal symptoms and corrected QT prolongation. Dose selection should include a careful consideration of the drugs' pharmacokinetic profiles and, when these are lacking therapeutic drug monitoring should be implemented as it is often a valid tool to optimize pediatric psychiatric practice.Keywords
This publication has 110 references indexed in Scilit:
- National Trends in Child and Adolescent Psychotropic Polypharmacy in Office-Based Practice, 1996-2007Journal of the American Academy of Child & Adolescent Psychiatry, 2010
- Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and AdolescentsJAMA, 2009
- Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)European Psychiatry, 2009
- Drug-Metabolizing Enzyme Genotypes and Aggressive Behavior Treatment Response in Hospitalized Pediatric Psychiatric PatientsJournal of Child and Adolescent Psychopharmacology, 2009
- Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescentsPharmacogenetics and Genomics, 2009
- Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapyChild and Adolescent Psychiatry and Mental Health, 2009
- Clozapine Versus “High-Dose” Olanzapine in Refractory Early-Onset Schizophrenia: An Open-Label Extension StudyJournal of Child and Adolescent Psychopharmacology, 2008
- Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?Current Opinion in Pediatrics, 2005
- AripiprazoleDrugs, 2004
- Pharmacokinetics of Pimozide in Adults and Children with Tourette's SyndromeThe Journal of Clinical Pharmacology, 1987